Press Releases for AKRX

Press Releases
Akorn Reports Third Quarter 2009 Financial Results; Launches Two New Products: Ketorolac Tromethamine Ophthalmic and Hydralazine HCL
Akorn Reports Second Quarter 2009 Financial Results
/C O R R E C T I O N -- Akorn, Inc./
Akorn, Inc. Announces Second Quarter 2009 Earnings Release and Conference Call Information
Akorn, Inc. Announces Second Quarter 2009 Earnings Release and Conference Call Information
Akorn Acquires Capastat® Sulfate from Eli Lilly and Company
Akorn Announces Management Changes
Akorn Reports First Quarter 2009 Financial Results
Akorn Issues Important Business Updates:-- Purchase of Existing Credit Facility ---- Renegotiation of Distribution Agreement --
Akorn Appoints Jeffrey A. Whitnell as Interim Chief Executive Officer
Akorn Appoints Raj Rai as Strategic Consultant
Akorn Amplifies Form 8-K Disclosure
Akorn Announces Management Change
Akorn-Strides, LLC Announces FDA Approvals for Sterile Vancomycin HCl USP, 500 mg/Vial; 1 g/Vial and Sterile Vancomycin HCl USP, 5 g/Vial Pharmacy Bulk Package
Akorn, Inc. Responds to FDA Draft Guidance for Industry on Bioequivalence Recommendation for Vancomycin HCl
Akorn, Inc. Announces FDA Approval of Ciprofloxacin HCl Ophthalmic Solution USP, 0.3%
Akorn, Inc. Signs Memorandum of Understanding with Bioluz S.A. for Five Premix Products
Akorn Enters into a Five Year Contract Manufacturing Agreement to Supply an Ophthalmic Product
Akorn, Inc. to Present at the Credit Suisse Healthcare Conference
Akorn Reports Record Third Quarter 2008 Revenues of $31.9 million; Earnings per Share of $0.03
Akorn-Strides, LLC Announces FDA Approval for Pamidronate Disodium Injection, 3 mg/mL and 9 mg/mL
Akorn, Inc. Announces FDA Approval of Adenosine Injection USP, 3 mg/mL
Akorn, Inc. to Present at the Oppenheimer 19th Annual Healthcare Conference
Akorn, Inc. Announces Third Quarter 2008 Earnings Release and Conference Call Information
Akorn, Inc. Announces the Launch of Akten(TM) Gel 3.5%
Akorn, Inc. Enters into a Commercial Manufacturing Supply Agreement
Akorn, Inc. Announces the FDA Approval of Akten(TM) Ophthalmic Gel 3.5%
Akorn Enters into an Exclusive Contract Manufacturing Supply Agreement - Sep 11 2008 9:32AM
Akorn, Inc. Announces First Lyophilized Product Approval For Decatur, IL: IC-Green(TM) for Injection, USP
Akorn-Strides, LLC Announces FDA Approvals for Dexamethasone Sodium Phosphate Injection USP, 4 mg (base)/mL and Dexamethasone Sodium Phosphate Injection USP, 10 mg (base)/mL
Akorn, Inc. to Present at the 2008 UBS Global Life Sciences Conference
Akorn Reports Second Quarter 2008 Financial Results
Akorn, Inc. Announces Second Quarter 2008 Earnings Release and Conference Call Information
Akorn-Strides, LLC Announces the First Commercial Product Launch for the Joint Venture, Rifampin for Injection
Akorn Enters into an Exclusive Contract Manufacturing Supply Agreement - Jul 9 2008 7:17AM
Akorn Enters into a Commercial Manufacturing Supply Agreement with Bioniche Pharma
Akorn, Inc. Announces Q2'08 Revenue Estimate and CDC Contract Award for Tetanus Diphtheria Vaccines
Akorn-Strides, LLC Announces FDA Approvals for Famotidine Injection USP, 20 mg/2mL Single-Dose Vials and Famotidine Injection USP, 40 mg/4mL & 200 mg/20 mL Multiple-Dose Vials
Akorn, Inc. Receives NDA Approvable Letter for Akten(R) Ophthalmic Gel 3.5%
Akorn, Inc. to Present at UBS Global Specialty and Generic Pharmaceuticals Conference
Akorn-Strides, LLC Announces FDA Approval for Rifampin for Injection USP, 600 mg/Vial - May 26 2008 10:32PM
Akorn-Strides, LLC Announces FDA Approval for Flumazenil Injection USP, 0.1 mg/mL - 5mL and 10 mL Multiple Dose Vials - Jun 1 2008 7:07AM
Akorn Reports First Quarter 2008 Financial Results - Jun 1 2008 7:07AM
Akorn, Inc. Announces First Quarter 2008 Earnings Release and Conference Call Information - Jun 1 2008 7:06AM
Akorn, Inc. to Present at Bank of America 2008 Health Care Conference
Akorn, Inc. to Present at Deutsche Bank Securities 33rd Annual Health Care Conference
Akorn-Strides, LLC Announces FDA Approvals for Ondansetron Injection USP, 4 mg/2mL Single Dose Vials and Ondansetron Injection USP, 40 mg/20mL Multiple Dose Vials
Akorn, Inc. Announces FDA Approval of Diclofenac Sodium Ophthalmic Solution 0.1%
Akorn, Inc. Announces FDA Approval of Ofloxacin Ophthalmic Solution USP, 0.3%
Akorn, Inc. Signs Supply Agreement with Fresenius Kabi for Premix Product